Key Takeaways; Cannabis Sector
- SNDL Reported “Particularly Challenging” First Quarter 2026 Financial and Operational Results
- Vireo Growth Accelerated Expansion with FLUENT Acquisition, Cementing its Florida Ambitions
- Aurora Cannabis Expanded Global Medical Portfolio with New International Product Launches
Key Takeaways; Psychedelic Sector
- Silo Pharma Sees Momentum as U.S. Accelerates Psychedelic PTSD Treatments
- Helus Pharma Expanded Veteran Outreach Through TARA Mind Partnership
Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.
Top Marijuana Companies for the Week
#1: SNDL
Canadian-based SNDL Inc. (NASDAQ: SNDL) reported a difficult first quarter for 2026, as weakening demand across both cannabis and liquor segments pressured revenue and profitability despite ongoing cost controls and strategic initiatives.
The company posted net revenue of $195.9 million for the three months ending March 31, 2026, marking a 4.4% year-over-year decline. Gross profit fell to $52.8 million, down 6.8%, while operating loss improved to $9.1 million from $12.1 million a year earlier, reflecting the absence of prior restructuring charges and tighter cost management.
SNDL Chief Executive Officer, Zach George, described the quarter in stark terms: “Beyond the normal seasonality that impacts the first quarter each year, Q1 2026 was particularly challenging, driven primarily by market softness across our business segments and operating territories.” He added that the company is “proactively adjusting our commercial execution and cost structure to reflect the reality of current market conditions.”
SNDL’s cannabis operations generated $91.8 million in net revenue after intersegment eliminations, down 3.8% from the prior year. Retail remained relatively stable at $77.3 million, supported by new store additions and acquisitions, though same-store sales declined by 2.5%. Overall, the cannabis segment recorded a combined operating loss of $5.8 million, widening from the previous year.
A notable bright spot was international cannabis sales, which rose 94% year-over-year to $3.5 million, partially offsetting domestic weakness.
SNDL’s liquor retail division, which was the largest contributor to total revenue at $104.1 million, saw a 4.9% decline due to weaker consumer demand and a 6.1% drop in same-store sales. While margins improved slightly through private-label expansion and operational efficiencies, the segment posted a larger operating loss of $3.2 million.
The company reported negative operating cash flow of $26.7 million and free cash flow of negative $7.6 million, driven by inventory build-up and continued investments. Share repurchases and acquisitions also contributed to cash outflows.
Despite this, SNDL maintained a strong balance sheet, ending the quarter with over $213 million in unrestricted cash and no debt. The company emphasized its ability to pursue growth opportunities and strategic investments amid industry consolidation.
“We are uniquely positioned to deploy capital across both organic and inorganic opportunities to further enhance our portfolio and accelerate growth,” George said, highlighting disciplined capital allocation as a key priority.
Looking ahead, management remains cautiously optimistic. While near-term market conditions remain challenging, SNDL expects improvement in the second half of 2026, supported by industry developments, strategic execution, and potential regulatory tailwinds in North America.
#2: Vireo Growth
Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) continued its aggressive expansion strategy with the announced acquisition of FLUENT Corp. in an all-stock transaction, a move that significantly strengthened its footprint in Florida’s lucrative medical cannabis market.
Under the agreement, Vireo will acquire all outstanding FLUENT shares, with shareholders receiving approximately 0.07 Vireo subordinate voting shares for each FLUENT share held. The deal also includes the conversion of roughly $30 million in FLUENT’s debt into equity, allowing lenders to participate in the combined company’s future upside. The transaction remains subject to shareholders, court, and regulatory approvals, with closing expected in late 2026.
The acquisition is set to elevate Vireo into one of Florida’s largest medical cannabis operators. By combining FLUENT’s network with its earlier purchase of Eaze, which operated 41 stores in the state under the Green Dragon brand, Vireo expects to operate around 74 dispensaries in the state, supported by expanded cultivation and production capacity.
Vireo CEO, John Mazarakis, emphasized the strategic rationale, stating, “Florida’s limited-license structure rewards scale, and combining two complementary networks with minimal overlap creates a platform that is meaningfully harder to replicate.” He added that FLUENT’s existing operations, which generated about $71.5 million in Florida revenue, provide “a structurally improved asset at an attractive entry point.”
FLUENT leadership also framed the deal as a pathway to greater competitiveness. Interim CEO David E. Vautrin said, “Partnering with a materially larger cannabis company provides the scale, capital, and infrastructure needed to accelerate growth,” while enabling shareholders to “participate in the upside of a stronger, scaled platform.” The company’s board unanimously supported the transaction following an independent review, citing its strategic and financial benefits.
Ahead of closing, FLUENT plans operational changes to “right-size” the business, including cost reductions and potential divestitures of non-core assets. These measures are intended to improve efficiency and cash flow generation before integration into Vireo’s broader platform.
The deal marked the latest step in Vireo’s rapid consolidation push, which has included multiple acquisitions across key U.S. markets; including the company’s recent strategic acquisition of Hawthorne from The Scotts Miracle-Gro Company (NYSE: SMG). With Florida remaining the largest medical-only cannabis market in the country, despite stalled legalization efforts, Vireo is betting that scale and operational discipline will position it among the industry’s leading players.
#3: Aurora Cannabis
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) accelerated its global medical cannabis strategy with a wave of new product launches across Canada, Europe, and Australia, reinforcing its focus on regulated markets and patient-driven innovation.
The expansion introduced a broader range of formats, including dried flower, pre-rolls, and pastilles, tailored to meet growing demand from both patients and prescribers. The rollout, scheduled through June, leverages Aurora’s global network of GMP-certified manufacturing facilities to ensure consistent quality and supply across regions.
According to Lana Culley, VP Innovation & International Operations at Aurora, the initiative reflects a deliberate response to market needs. “As our global medical business continues to grow, our focus remains on delivering consistency and reliability across the markets we serve,” she said. “By expanding our offerings in key countries, we’re responding to clear patient and prescriber demand – all while reinforcing the level of quality and trust expected from us.”
In Europe, Aurora strengthened its presence with new high-THC cultivars in Germany and an expanded potency range in Poland, addressing increasing demand for differentiated medical cannabis options. Meanwhile, in Australia, the company announced that it is introducing precisely dosed pastilles, which is an alternative format designed for discretion and longer-lasting effects.
In Canada, Aurora stated that it continues to build out its core medical portfolio with new dried flower strains and pre-rolls under established brands, emphasizing variety and potency. According to Aurora, these launches are aligned with the company’s “medical-first” approach, prioritizing patient choice and product consistency. By combining innovation in product formats with a reliable global supply chain, the company aims to solidify its position as a leading provider in the evolving medical cannabis landscape.
Top Psychedelic Companies for Week
#1: Silo Pharma
Silo Pharma, Inc. (NASDAQ: SILO) announced on Thursday that its PTSD-focused development efforts are gaining momentum as U.S. federal agencies move to fast-track psychedelic-based therapies for mental health and substance use disorders. In a press release, the company highlighted a series of recent coordinated actions that aim to accelerate research, clinical development, and regulatory clarity across the sector.
At first, the company highlighted a key development that came from Advanced Research Projects Agency for Health, which announced initial awardees under its $139.4 million EVIDENT program, which included Johns Hopkins University and other leaders in psychedelic science. Silo believes this funding reinforces the importance of data-driven approaches in tackling complex neurological and psychiatric conditions.
Silo also highlighted the recent major development in psychedelic sector whereby the U.S. Food and Drug Administration (FDA) granted investigational new drug clearance to DemeRx NB’s noribogaine candidate for alcohol use disorder, signaling continued expansion of clinical-stage mental health treatments. Moreover, the FDA also issued Commissioner’s National Priority Vouchers to 3 companies including Compass Pathways plc (NASDAQ: CMPS), Usona Institute, and Transcend Therapeutics, highlighting a broader push to accelerate high-impact therapies, particularly those targeting PTSD.
Silo CEO Eric Weisblum emphasized the significance of these developments, stating, “We are witnessing a coordinated and accelerating shift at the federal level. From funding and clinical advancement to regulatory prioritization, in our opinion the foundation is being laid for a new generation of therapies that could transform how we treat PTSD and related disorders.”
The company also pointed to anticipated FDA guidance on psychedelic drug development, which is expected soon, as a critical milestone that could provide clearer pathways for researchers and sponsors.
#2: Helus Pharma
HELUS Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc. announced a new collaboration with TARA Mind aimed at advancing recruitment for its late-stage depression program while increasing mental health awareness among veterans. According to Helus, the partnership focuses on supporting the PARADIGM HLP003 Phase 3 trial for major depressive disorder (MDD), which is a key asset in the company’s pipeline.
The initiative came amid broader U.S. policy momentum following President Donald Trump’s Executive Order, “Accelerating Medical Treatments for Serious Mental Illness,” which prioritizes expanding clinical research participation and accelerating innovative therapies for underserved populations, including veterans. Helus Pharma sees its collaboration as closely aligned with these federal objectives.
Through the partnership, TARA Mind will leverage its established networks to improve veteran engagement and facilitate participation in the ongoing Phase 3 trial. Moreover, the company stated that the effort is designed not only to boost recruitment but also to connect veterans with emerging treatment options and mental health resources.
Helus Pharma Interim Chief Executive Officer, Eric So, emphasized the importance of the initiative, stating, “Veterans face significant mental health challenges, and expanding awareness and access to clinical research opportunities is an important step toward improving outcomes.” He added that TARA Mind’s experience with veteran communities will help “support recruitment efforts for our FDA Breakthrough Therapy-designated HLP003 program while aligning with broader priorities to expand research participation and advance innovative treatments for serious mental illness.”
TARA Mind leadership echoed this perspective. Chairman and co-founder Marcus Capone said the recent policy developments highlight the urgency of addressing veteran mental health needs. “Partnerships like this help strengthen outreach efforts, connect veterans to cutting-edge clinical opportunities, and ensure veterans have the latest resources that support their mental health,” he noted.
Helus Pharma’s HLP003, which is a novel serotonergic agonist designed to promote neuroplasticity, has already received Breakthrough Therapy designation from the U.S. Food and Drug Administration. The company views the collaboration as part of its broader commitment to patient-centric innovation and addressing significant unmet needs in depression and other mental health disorders.